AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 28, 2025

Conditions
HyperkalemiaChronic Kidney Disease (Stage 3-4)
Interventions
DEVICE

AK+ Guard™ ECG Application

An investigational Software as a Medical Device (SaMD) that analyzes Lead I electrocardiogram (ECG) data using artificial intelligence to detect moderate to severe hyperkalemia (serum potassium ≥ 6.5 mmol/L). ECG inputs may be obtained from standard 12-lead ECGs, clinical-grade ECG devices with Lead I capability, or consumer wearable devices (e.g., Apple Watch, HeartBeam).

Trial Locations (1)

07724

RECRUITING

Central Jersey Kidney Care - Hypertension & Nephrology Associates, Eatontown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AccurKardia, Inc.

INDUSTRY